InsidersTradesSigma
Total declarations
Companies
▲ Purchases (0 ops.)
▼ Sales (10 ops.)
Insider track record
ExecutiveDisclosed buys
0
Disclosed sells
10
Not enough buy signals with a settled T+90 horizon to measure a track record yet.
Signal history
Explore the full record of transactions filed by Iwicki Mark T, Director. Officer active across 4 companies, notably Akero Therapeutics, Inc.. Aggregated, 18 filings have been published. Split: 0 buy · 10 sells. Total volume traded: €296k. Activity tracked since 28 June 2021. The latest transaction was disclosed on 6 January 2025 (Attribution). Regulator: SEC (Form 4). The full history is free.
Declarations18 total
9,398 sharesCommon StockSEC:0001193125-25-312115
9,398 sharesCommon StockSEC:0001193125-25-312115:0
22,100 shares0Common StockSEC:0001415889-25-001060:0
15,168 shares@ US$4.7561.9% of flowCommon StockSEC:0001415889-24-018374:0
7,392 shares@ US$6.0938.1% of flowCommon StockSEC:0001415889-24-015222:0
14,300 shares0Common StockSEC:0001415889-24-000769:0
158,873 shares0Common StockSEC:0001415889-23-010281:0
71,715 sharesCommon StockSEC:0001415889-23-009133:0
36,944 shares@ US$6.57100.0% of flowCommon SharesSEC:0001209191-23-024393:0
41,700 shares0Common StockSEC:0001415889-23-000636:0
561 shares@ US$6.521.9% of flowCommon StockSEC:0001415889-22-010878:0
7,975 shares@ US$0.370.018% mcap1.5% of flowCommon StockSEC:0001415889-22-007059:0
9,518 shares@ US$1.3012.1% of flowCommon StockSEC:0001415889-22-000402
9,518 shares@ US$1.300.071% mcap6.0% of flowCommon StockSEC:0001415889-22-000402:0
27,598 shares@ US$1.800.28% mcap23.3% of flowCommon StockSEC:0001415889-21-005009:0
27,598 shares@ US$1.8047.3% of flowCommon StockSEC:0001415889-21-005009
7,586 shares@ US$5.7719.6% of flowCommon StockSEC:0001415889-21-003256
7,586 shares@ US$5.770.24% mcap20.0% of flowCommon StockSEC:0001415889-21-003256:0
18 of 18 declarations
About Iwicki Mark T
Iwicki Mark T is the Chief Executive Officer of Akero Therapeutics, Inc. and Kala Pharmaceuticals, Inc. He leads the strategic and operational activities of these companies, focusing on innovation and growth. With a strong background in the pharmaceutical sector, he is responsible for formulating business strategies and overseeing the executive teams. His leadership is essential for achieving the company’s objectives and ensuring value creation for shareholders.
